|
| 产品描述 |
| Ibrutinib, also known as PCI-32765, is a BTK inhibitor, is also a n orally bioavailable small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. BTK inhibitor PCI-32765 binds to and inhibits BTK activity, preventing B-cell activation and B-cell-mediated signaling and inhibiting the growth of malignant B cells that overexpress BTK. Ibrutinib was approved by the US FDA on November 13, 2013 for the treatment of mantle cell lymphoma. |
| 化学结构 |
 |
| 化学名称 |
| (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one. |
| SMILES Code |
| C=CC(N1C[C@H](N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C5=C(N)N=CN=C52)CCC1)=O |
| 基本信息 |
产品编号:XM033
产品名称:Ibrutinib
别名:PCI32765; PCI-32765; PCI 32765; Ibrutinib. Brand name: Imbruvica
CAS#:936563-96-1
分子式:C25H24N6O2
精确分子量:440.19607
分子量:440.49706
|
| 物化性质 |
外观: 白色固体
纯度: >98%
运输信息: 非危险化学品，适于常温或冰袋运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限:3 年 -20℃固体储存
2 年 -80℃ 溶液储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
